Surgery-ready lung cancer treatment with immunotherapy plus chemo
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies adding an immunotherapy drug (sintilimab) to standard chemotherapy before surgery for resectable squamous non-small cell lung cancer. It aims to shrink the tumor and improve outcomes, while still keeping the cancer operable.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old, and can attend all planned visits and tests.
- Your lung cancer is confirmed as squamous non-small cell lung cancer from biopsy or fluid testing.
- Your cancer stage is considered resectable (AJCC stage IIA to IIIB) and you have not had treatment for it yet.
- Your performance status is ECOG 0–1 (you’re active enough for treatment).
- Your main blood and organ tests are adequate (white blood cells, platelets, hemoglobin, liver/kidney numbers, and blood clotting).
- You likely cannot have had prior immunotherapy that blocks PD-1/PD-L1/PD-L2 or related immune-targeting drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining two immunotherapy drugs (anti-CTLA-4 antibody and sintilimab) with chemotherapy before surgery for stage II-III non-small cell lung cancer. The goal is to see if this approach helps shrink tumors and improve outcomes.
This trial tests a combination of three drugs (tislelizumab, anlotinib, and chemotherapy) given before and after surgery to treat stage II-IIIB non-small cell lung cancer. The goal is to see if this approach can improve outcomes for patients whose cancer can be removed surgically.
This trial tests whether giving more immunotherapy after surgery can help people with non-small cell lung cancer who still had some cancer cells left after their first round of immunotherapy and chemotherapy before surgery. It aims to improve outcomes for those whose tumor didn't fully disappear.
This Phase 2 trial tests an “immunotherapy” medicine given before surgery for stage III non-small cell lung cancer. The goal is to shrink the cancer and make curative surgery more successful while monitoring safety and response.
This study tests whether giving sintilimab (an immune therapy) combined with bevacizumab (a blood-vessel–targeting medicine) plus chemotherapy before surgery can improve outcomes for resectable lung cancer. It’s meant for people with specific lung cancer types and good health for surgery, and it avoids certain cancer types and immune-related risks.
This trial tests giving chemotherapy followed by the immunotherapy drug sintilimab before surgery for people with EGFR-mutant, early-stage non-small cell lung cancer. It aims to see if this combination reduces the tumor and improves outcomes before surgical removal.
Hear when a new Squamous Cell Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.